Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach.

被引：0
|
作者：
Namour, Florence [1 ]
Tasset, Chantal [2 ]
Vayssierre, Beatrice [1 ]
van 't Klooster, Gerben [2 ]
Diderichsen, Paul [3 ]
Cox, Eugene [3 ]
机构：
[1] Galapagos SASU, Romainville, France
[2] Galapagos NV, Mechelen, Belgium
[3] Quantitat Solut, Breda, Netherlands
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1480
引用
收藏
页码：S650 / S651
页数：2
相关论文
共 27 条
  • [1] DOSE SELECTION OF GLPG0634, A SELECTIVE JAK1 INHIBITOR, FOR RHEUMATOID ARTHRITIS PHASE 2B STUDIES: PK/PD AND EXPOSURE-DAS28 MODELING APPROACH
    Namour, F.
    Tasset, C.
    van't Klooster, G.
    Diderichsen, P. M.
    Cox, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 220 - 221
  • [2] Dose Selection of Filgotinib, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 3 Studies: Exposure-DAS28 and ACR Modeling Approach
    Florence, Namour
    Diderichsen, Paul
    Cox, Eugene
    Sharma, Shringi
    Tasset, Chantal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [3] Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
    Florence Namour
    Paul Matthias Diderichsen
    Eugène Cox
    Béatrice Vayssière
    Annegret Van der Aa
    Chantal Tasset
    Gerben Van‘t Klooster
    Clinical Pharmacokinetics, 2015, 54 : 859 - 874
  • [4] Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
    Namour, Florence
    Diderichsen, Paul Matthias
    Cox, Eugene
    Vayssiere, Beatrice
    Van der Aa, Annegret
    Tasset, Chantal
    Van't Klooster, Gerben
    CLINICAL PHARMACOKINETICS, 2015, 54 (08) : 859 - 874
  • [5] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
    Kavanaugh, Arthur
    Ponce, Lucia
    Cseuz, Regina
    Reshetko, Olga
    Stanislavchuk, Mykola A.
    Greenwald, Maria
    Van der Aa, Annegret
    Vanhoutte, Frederic
    Tasset, Chantal
    Harrison, Pille
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [6] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
    Westhovens, R.
    Alten, Rieke
    Pavlova, Dace
    Enriquez-Sosa, Favio
    Mazur, Minodora
    Greenwald, Maria
    Van der Aa, Annegret
    Vanhoutte, Frederic
    Tasset, Chantal
    Harrison, Pille
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] FILGOTINIB (GLPG0634), A SELECTIVE JAK1 INHIBITOR, SHOWS SIMILAR PK AND PD PROFILES IN JAPANESE AND CAUCASIAN HEALTHY VOLUNTEERS
    Namour, F.
    Vayssiere, B.
    Galien, R.
    Fagard, L.
    Van der Aa, A.
    Harrison, P.
    Tasset, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1063 - 1064
  • [8] Comment on: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
    Nuggehally R. Srinivas
    Clinical Pharmacokinetics, 2015, 54 : 1293 - 1295
  • [9] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE AS MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
    Kavanaugh, A.
    Ponce, L.
    Cseuz, R.
    Reshetko, O.
    Stanislavchuk, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 247 - 247
  • [10] Comment on: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection"
    Srinivas, Nuggehally R.
    CLINICAL PHARMACOKINETICS, 2015, 54 (12) : 1293 - 1295
123